JO3380B1 - مشابهات ابيلين اصطناعية لعلاج قصور القلب - Google Patents

مشابهات ابيلين اصطناعية لعلاج قصور القلب

Info

Publication number
JO3380B1
JO3380B1 JOP/2013/0027A JOP20130027A JO3380B1 JO 3380 B1 JO3380 B1 JO 3380B1 JO P20130027 A JOP20130027 A JO P20130027A JO 3380 B1 JO3380 B1 JO 3380B1
Authority
JO
Jordan
Prior art keywords
heart failure
treatment
polypeptides
diabetes
hypertension
Prior art date
Application number
JOP/2013/0027A
Other languages
English (en)
Inventor
Golosov Andrei
Thomas Parker David
Zecri Frédéric
Grosche Philipp
Yasoshima Kayo
Hu Qi-Ying
Imase Hidetomo
Zhao Hongjuan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3380(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3380B1 publication Critical patent/JO3380B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A61M16/0066—Blowers or centrifugal pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/201—Controlled valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)

Abstract

يقدم الإختراع عديد البيبتيد التخليقي من الصيغة I': I’ أو أميد، إستر أو ملح منه، حيث تم تحديدX1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 و X13 هنا. عديدات البيبتيد هي عبارة عن مناهضات لمستقبل APJ. يتعلق الإختراع أيضا بطريقة لصناعة عديد البيبتيد الخاص بالإختراع، وإستخداماته العلاجية مثل العلاج أو الوقاية من فشل القلب الحاد (ADHF)، فشل القلب المزمن، سرعة ضربات القلب البطيني، تصلب الشرايين، إرتفاع ضغط الدم، أمراض فشل القلب والأوعية، إعتلال عضلة القلب، تليف القلب، عدم إنتظام ضربات القلب، مرض السكري (ويتضمن سكر الحمل)، السمنة، مرض الشريان الطرفي، حوادث الأوعية الدماغية، النوبات الإقفارية المؤقتة، إصابات المخ الإصطدامية، تصلب الشرايين الجانبي الضموري، إصابات الحرق (ويتضمن حروق الشمس) و تسمم الحمل. يقدم الإختراع الحالي أيضا تركيب من العوامل النشطة فارماكولوجيا وتركيب صيدلي.
JOP/2013/0027A 2012-01-27 2013-01-24 مشابهات ابيلين اصطناعية لعلاج قصور القلب JO3380B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591557P 2012-01-27 2012-01-27
US201261717760P 2012-10-24 2012-10-24
US201261731697P 2012-11-30 2012-11-30

Publications (1)

Publication Number Publication Date
JO3380B1 true JO3380B1 (ar) 2019-03-13

Family

ID=47997598

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0027A JO3380B1 (ar) 2012-01-27 2013-01-24 مشابهات ابيلين اصطناعية لعلاج قصور القلب

Country Status (43)

Country Link
US (4) US8673848B2 (ar)
EP (1) EP2807183B1 (ar)
JP (2) JP6313222B2 (ar)
KR (2) KR102068370B1 (ar)
CN (1) CN104220452B (ar)
AP (1) AP2014007846A0 (ar)
AR (1) AR089808A1 (ar)
AU (1) AU2013213265C1 (ar)
BR (1) BR112014018306A8 (ar)
CA (1) CA2862240A1 (ar)
CL (1) CL2014001994A1 (ar)
CO (1) CO7020879A2 (ar)
CR (1) CR20140364A (ar)
CU (1) CU24266B1 (ar)
CY (1) CY1120239T1 (ar)
DK (1) DK2807183T3 (ar)
EA (1) EA027853B1 (ar)
EC (1) ECSP14016014A (ar)
ES (1) ES2670832T3 (ar)
GT (1) GT201400166A (ar)
HK (1) HK1200470A1 (ar)
HR (1) HRP20180806T1 (ar)
HU (1) HUE039137T2 (ar)
IL (1) IL233792B (ar)
JO (1) JO3380B1 (ar)
LT (1) LT2807183T (ar)
MX (1) MX351569B (ar)
MY (1) MY172268A (ar)
NZ (1) NZ627772A (ar)
PE (1) PE20142194A1 (ar)
PH (1) PH12014501701A1 (ar)
PL (1) PL2807183T3 (ar)
PT (1) PT2807183T (ar)
RS (1) RS57200B1 (ar)
SG (1) SG11201404369PA (ar)
SI (1) SI2807183T1 (ar)
TN (1) TN2014000318A1 (ar)
TR (1) TR201807309T4 (ar)
TW (1) TWI576356B (ar)
UA (1) UA116196C2 (ar)
UY (1) UY34593A (ar)
WO (1) WO2013111110A2 (ar)
ZA (1) ZA201405400B (ar)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP3470104B1 (en) 2011-07-13 2023-01-25 Fisher & Paykel Healthcare Limited Impeller and motor assembly
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
IN2015DN02913A (ar) 2012-11-30 2015-09-18 Novartis Ag
AU2013101734A4 (en) 2012-12-18 2015-09-24 Fisher & Paykel Healthcare Limited Impeller and motor assembly
EP3907237A1 (en) * 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
EP2970415B1 (en) * 2013-03-14 2018-12-19 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
WO2015013168A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024846A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
JP6483117B2 (ja) 2013-11-20 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ａｐｌｎｒモジュレーター及びその使用
US10172948B2 (en) * 2013-11-26 2019-01-08 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
CA2941080A1 (en) 2014-03-25 2015-10-01 Lanthiopep B.V. Cyclic apelin analogs
GB201407532D0 (en) 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
ES2792598T3 (es) * 2014-05-23 2020-11-11 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3851445A1 (en) 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
USD790683S1 (en) * 2015-03-11 2017-06-27 Resmed Limited Pressurized air delivery console
EP3273981B1 (en) * 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
RS60353B1 (sr) 2015-05-20 2020-07-31 Amgen Inc Agonisti triazola apj receptora
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018075822A1 (en) 2016-10-19 2018-04-26 Avive, Inc. Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11400247B2 (en) 2016-12-22 2022-08-02 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11401974B2 (en) 2017-04-23 2022-08-02 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CN117563098A (zh) 2017-10-06 2024-02-20 斐雪派克医疗保健有限公司 呼吸设备
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP3880680A1 (en) 2018-11-14 2021-09-22 Altavant Sciences GmbH A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
EP3701992B1 (en) * 2019-02-27 2023-07-05 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Gas delivery device with deformable bag and differential pressure sensors
CN112007027B (zh) * 2020-09-14 2022-07-15 长春金赛药业有限责任公司 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
GB2281513B (en) * 1993-08-31 1997-12-03 Ulco Eng Pty Ltd Ventilator disconnect alarm
EP0645119A3 (en) * 1993-09-27 1998-04-15 Ohmeda Inc. Disabling apnoea volume software
US5598838A (en) * 1995-04-07 1997-02-04 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
CA2222830C (en) * 1996-12-02 2004-03-30 Fisher & Paykel Limited Humidifier sleep apnea treatment apparatus
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999033976A1 (en) 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, their production and use
AU5759399A (en) 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
WO2000020439A1 (fr) 1998-10-05 2000-04-13 Takeda Chemical Industries, Ltd. Procede d'elimination de methionine n-terminale
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
AU2001242749A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Peptide derivative
WO2001090123A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
US7574368B2 (en) * 2000-12-15 2009-08-11 Ric Investments, Llc System and method for upgrading a pressure generating system
ATE421091T1 (de) 2001-07-16 2009-01-15 Caprotec Bioanalytics Gmbh Fangverbindungen, ihre entnahme und verfahren zur analysierung des proteoms und von komplexen zusammensetzungen
US7157035B2 (en) * 2001-12-14 2007-01-02 Fisher & Paykel Healthcare Limited Method of forming a respiratory conduit
TW545624U (en) * 2002-01-18 2003-08-01 Enermax Technology Corp Computer environment temperature/rotation speed display and self-adjusted fan speed device
WO2003063892A1 (fr) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Utilisation d'apeline
US7086399B2 (en) * 2002-05-29 2006-08-08 Fisher & Paykel Healthcare Limited Apparatus for delivery of humidified gases therapy, associated methods and analysis tools
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US20050152836A1 (en) 2003-05-22 2005-07-14 Euan Ashley Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20080139481A1 (en) 2004-06-17 2008-06-12 Dix Thomas A Non-Natural Amino Acids
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
US20110097710A1 (en) 2004-10-26 2011-04-28 Macrae Calum A Methods for detecting atrial fibrillation and related conditions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
EP2017355A4 (en) 2006-04-25 2010-01-06 Univ Kyushu Nat Univ Corp ASSOCIATED WITH ARTERIOSCLEROSIS DISEASE AND USE THEREOF
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187935A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP2362878A4 (en) 2008-11-04 2015-09-16 Anchor Therapeutics Inc APJ RECEPTOR COMPOUNDS
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
US20150011466A1 (en) 2012-01-09 2015-01-08 Anchor Therapeutics, Inc. APJ Receptor Compounds
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013168A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides

Also Published As

Publication number Publication date
US20130196899A1 (en) 2013-08-01
ZA201405400B (en) 2016-08-31
WO2013111110A3 (en) 2013-10-31
KR20140117603A (ko) 2014-10-07
LT2807183T (lt) 2018-05-10
PH12014501701A1 (en) 2014-10-13
MY172268A (en) 2019-11-20
ES2670832T3 (es) 2018-06-01
AU2013213265A1 (en) 2014-09-18
UY34593A (es) 2013-09-02
EA027853B1 (ru) 2017-09-29
MX2014009085A (es) 2014-08-27
US9067971B2 (en) 2015-06-30
HRP20180806T1 (hr) 2018-06-29
RS57200B1 (sr) 2018-07-31
US8673848B2 (en) 2014-03-18
CN104220452A (zh) 2014-12-17
CY1120239T1 (el) 2019-07-10
WO2013111110A2 (en) 2013-08-01
CO7020879A2 (es) 2014-08-11
AR089808A1 (es) 2014-09-17
US20170232221A1 (en) 2017-08-17
BR112014018306A8 (pt) 2017-07-11
HUE039137T2 (hu) 2018-12-28
CA2862240A1 (en) 2013-08-01
KR102068370B1 (ko) 2020-01-21
TN2014000318A1 (en) 2015-12-21
TW201335190A (zh) 2013-09-01
ECSP14016014A (es) 2015-11-30
SI2807183T1 (en) 2018-05-31
CN104220452B (zh) 2018-01-26
JP2015506370A (ja) 2015-03-02
CU24266B1 (es) 2017-07-04
JP6313222B2 (ja) 2018-04-18
DK2807183T3 (en) 2018-06-06
NZ627772A (en) 2015-11-27
US9982017B2 (en) 2018-05-29
GT201400166A (es) 2015-10-15
SG11201404369PA (en) 2014-08-28
EP2807183B1 (en) 2018-02-28
AP2014007846A0 (en) 2014-08-31
HK1200470A1 (en) 2015-08-07
CU20140097A7 (es) 2015-03-30
US20140142022A1 (en) 2014-05-22
IL233792B (en) 2018-04-30
EA201491433A1 (ru) 2014-12-30
MX351569B (es) 2017-10-19
CL2014001994A1 (es) 2014-11-03
BR112014018306A2 (ar) 2017-06-20
EP2807183A2 (en) 2014-12-03
AU2013213265B2 (en) 2016-05-26
JP6595553B2 (ja) 2019-10-23
US20150252076A1 (en) 2015-09-10
JP2018048157A (ja) 2018-03-29
KR20200003229A (ko) 2020-01-08
PE20142194A1 (es) 2014-12-21
IL233792A0 (en) 2014-09-30
PT2807183T (pt) 2018-05-29
AU2013213265C1 (en) 2016-09-29
UA116196C2 (uk) 2018-02-26
TWI576356B (zh) 2017-04-01
PL2807183T3 (pl) 2018-08-31
CR20140364A (es) 2014-11-17
TR201807309T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
JO3380B1 (ar) مشابهات ابيلين اصطناعية لعلاج قصور القلب
PH12016500103A1 (en) Bioconjugates of synthetic apelin polypeptides
PH12016500104A1 (en) Cyclic polypeptides for the treatment of heart failure
JP2018048157A5 (ar)
JP2016053040A5 (ar)
UY33288A (es) Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
PH12017501112A1 (en) Synthetic apelin fatty acid conjugates with improved half-life
NZ597024A (en) Cardiovascular related uses of il-1beta antibodies and binding fragments thereof
TN2016000029A1 (en) Bioconjugates of synthetic apelin polypeptides
WO2013048116A3 (ko) 에리스로포이에틴-유래 펩타이드 및 그 용도
MA38864A1 (fr) Polypeptides cycliques pour le traitement de l'insuffisance cardiaque
WO2012059942A3 (en) Dynamic balancing of autonomic nervous system through vitamin mk-7
Tolpygina Possibility ofhigh-selective adrenoblockers use in combined therapy of patients with metabolic syndrome
Aizawa et al. Atrial Fibrillation Revisited—With a Special Reference to Primary Prevention—
WO2018051294A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies
Alexopoulos et al. Intensive, but not moderate, statin therapy lowers epicardial adipose tissue